Understanding the role of ATP and P2X3 receptors in chronic cough
Official title: Neuroinflammatory Interactions of ATP and P2X3 Receptor in the Airways of Chronic Cough Patients: an Exploratory Study
Run by Imperial College London · NCT06286163 · Data updated 2026-11-12
This study is trying to understand what causes chronic cough by looking at lung inflammation and a specific molecule in people with the cough compared to healthy individuals.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 30 Years to 70 Years |
| Sex | All |
| Enrollment | 18 (estimated) |
| Sponsor | Imperial College London Academic / other |
| Locations | 2 sites (London and 1 other locations) |
| Status | Recruiting |
| Started | October 1, 2023 |
| Main results expected | December 31, 2025 |
| Study ends | December 31, 2025 |
| Registry record updated | February 7, 2025 |
| Trial ID | NCT06286163 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include individuals with a chronic cough lasting at least 8 weeks and those who have been evaluated in a Cough Clinic.
✕Probably not a fit
Patients with significant respiratory diseases or those who have not been diagnosed with chronic cough may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to investigate the underlying causes of chronic cough, defined as a cough lasting more than 8 weeks. Researchers will compare the lung inflammation and potential involvement of adenosine triphosphate (ATP) in patients with chronic cough to healthy individuals without the condition. The study will involve 10 participants suffering from chronic cough and 8 healthy controls to identify abnormalities associated with chronic cough. By examining these interactions, the research seeks to enhance understanding of this common yet poorly understood condition.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding and potentially new treatment options for patients suffering from chronic cough.
How similar studies have gone: While the approach is novel in its specific focus on ATP and P2X3 receptors, similar studies have explored chronic cough, but this particular interaction has not been extensively tested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: \- 1. For Normal non-smoking subject: Healthy individuals, free of significant disease No history of asthma/rhinitis, No therapies, Baseline FEV1 ≥80% predicted with FEV1/FVC ratio \>70% Non-smoker for at least the past 12 months with a pack history of ≤5 pack-years 2\. For chronic cough participants: History of chronic cough of at least 8 weeks' duration and should have been followed in the Cough Clinic for at least 6 months. Undergone a protocol with a diagnostic pathway as recommended by the ERS guidelines for management of cough. Would have either an identifiable cause for their cough that have failed therapies targeted towards the identified cause or classed as having chronic idiopathic cough where no identifiable cause has been found. 3\. General Inclusion Criteria: Give written informed consent prior to participation in the study including all of its procedures. Comply with the requirements and restrictions listed in the consent form. Male or female subject aged between 30 and 70 years old at screening. Able to complete the study and all measurements. Able to read, comprehend, and write at a sufficient level to complete study related materials. Exclusion Criteria: \-
Where it's running
-
Royal Brompton & Harefield NHS Trust,
London, United Kingdom Recruiting -
Royal Brompton Hospital
London, United Kingdom Recruiting
Study contacts
- Principal investigator: Kian Fan Chung, MD — Imperial College London
- Study coordinator: Kian Fan Chung, MD
- Email: f.chung@imperial.ac.uk
- Phone: 442075947959
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Chronic Cough and Airway Remodelling in Refractory Cough Patients
This study tests whether long-lasting chronic cough damages and remodels the airways in adults who have had cough for over a year and have not responded to prior treatments.
-
Treatments for prolonged cough in children
It tests whether an inhaled steroid helps children with dry prolonged cough and whether an antibiotic helps children with wet prolonged cough compared with placebo.
-
Brief, breath-focused ACT for adults with chronic cough
This pilot test checks if a short, breath-control-oriented Acceptance and Commitment Therapy program is doable, acceptable, and safe for adults who have chronic cough.
-
Behavioral therapy for persistent chronic cough
This program will try behavioral cough suppression therapy to help adults whose cough has lasted more than eight weeks and has not improved with usual treatments.
-
Biomarkers and Respiratory Omics in Children: Predicting Disease Course
This study tests whether biomarkers from the lungs and blood can predict how asthma and protracted bacterial bronchitis in children will progress and respond to current therapies.
-
Evaluating treatment satisfaction with gefapixant for chronic cough
This study is testing how satisfied adults with stubborn chronic cough are with the treatment gefapixant and whether any taste changes they experience affect their quality of life related to coughing.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.